Replies to post #205174 on Biotech Values

[DewDiligence]

ADXS to receive $2.5M cash for NJ NOLs:

http://finance.yahoo.com/news/advaxis-receive-2-5m-jersey-120000605.html

New Jersey is one of the few jurisdictions that allows NOL tax credits to be sold for cash.

[DewDiligence]

Added ADXS at $8.96 (eom).

[ChikiTiny]

I listened to their analyst day webcast as a result of your reco and was very impressed with the company. I also bought a starter position. Look forward to following the story and digging deeper.

[DewDiligence]

ADXS begins phase-2 portion of Keytruda combination trial in CRPC:

http://finance.yahoo.com/news/advaxis-initiates-combination-portion-phase-113000202.html

Advaxis, Inc...today announced the commencement of Part B of the KEYNOTE-046 clinical trial evaluating Advaxis’ Lm immunotherapy candidate, ADXS-PSA, in combination with KEYTRUDA (pembrolizumab) in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). In Part A of the Phase 1/2 study, 14 patients were treated with ADXS-PSA monotherapy across three dose levels, with no dose limiting toxicities, paving the way for initiating Part B of the study.

KEYNOTE-046 is a multicenter, open-label, nonrandomized, dose determining, Phase 1/2 trial evaluating the safety of ADXS-PSA. Part B of the study is evaluating the tolerability of ADXS-PSA in combination with KEYTRUDA in 30 patients with mCRPC. Secondary objectives for this study are to evaluate antitumor activity and progression-free survival of ADXS-PSA. KEYNOTE-046 is the first-in-human study of Advaxis' Lm immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer.